Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · Real-Time Price · USD
0.5960
+0.0160 (2.76%)
At close: Sep 12, 2025, 4:00 PM EDT
0.5802
-0.0158 (-2.65%)
After-hours: Sep 12, 2025, 7:55 PM EDT
Virax Biolabs Group Revenue
In the fiscal year ending March 31, 2025, Virax Biolabs Group had annual revenue of $6.33K, down -95.95%. Virax Biolabs Group had revenue of $1.38K in the half year ending March 31, 2025, a decrease of -50.80%.
Revenue (ttm)
$6.33K
Revenue Growth
-95.95%
P/S Ratio
401.48
Revenue / Employee
$333
Employees
19
Market Cap
2.59M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 6.33K | -150.09K | -95.95% |
Mar 31, 2024 | 156.42K | 147.86K | 1,727.11% |
Mar 31, 2023 | 8.56K | - | - |
Mar 31, 2022 | - | - | - |
Mar 31, 2021 | 123.82K | 23.94K | 23.97% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
VRAX News
- 17 days ago - Virax Biolabs Partners with Emory University on ViraxImmune™ Clinical Studies; Readies for FDA Pre-Submission Meeting in Early September - PRNewsWire
- 6 weeks ago - Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial Strategy - PRNewsWire
- 2 months ago - Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency - PRNewsWire
- 5 months ago - Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating - Benzinga
- 6 months ago - Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes - PRNewsWire
- 6 months ago - Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting - PRNewsWire
- 6 months ago - Virax Biolabs to Present at 19th World Immune Regulation Meeting - PRNewsWire
- 7 months ago - Virax Biolabs Believes Technology Aligns with United States Department of Health and Human Services' Transparency Priority on Vaccine Efficacy - PRNewsWire